Ubaldo, 31 patient HCQ ICU study: 18% lower mortality [p=0.64] https://c19p.org/ubaldo
copied to clipboard
COVID-19: A Single-Center ICU Experience of the First Wave in the Philippines
et al., Critical Care Research and Practice, 10.1155/2021/7510306
Retrospective ICU patients in the Philippines showing unadjusted HCQ RR 0.82, p = 0.64.
|
risk of death, 18.4% lower, RR 0.82, p = 0.64, treatment 17 of 25 (68.0%), control 5 of 6 (83.3%), NNT 6.5, COVID-19 positive patients.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
substantial unadjusted confounding by indication likely, very late stage, ICU patients, unadjusted results with no group details.
Ubaldo et al., 2/1/2021, retrospective, Philippines, Asia, peer-reviewed, 3 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.